Clinical trials: Gastrointestinal Infection
Hepatitis B, Chronic
Safety and Antiviral Activity Study of ACH-126,443 (Beta-L-Fd4C) in Treatment-naive Adults With Chronic Hepatitis B Virus Infection
The purpose of this study was to determine the safety and anti-hepatitis B virus (-HBV) activity of ACH-126,443 in comparison to lamivudine or placebo in treatment-naive adults with chronic hepatitis B infection.
- Trial name
- NCT00034359
- Testing
- ACH-126,443, Lamivudine
- Where
- 3 sites in Bulgaria, Federal Republic of Yugoslavia
- Volunteers
- 79 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Cystic Fibrosis Lung, Respiratory Infections, Recurrent, Chronic
A Double-Blind, Active-Controlled, Multiple-Ascending Dose Study of Aerosolized RSP-1502 in Subjects With CF and Chronic PA Lung Infection
A double-blind, active-controlled, multiple-ascending dose, safety study of aerosolized RSP-1502 in subjects with cystic fibrosis Pseudomonas aeruginosa lung infection.
- Conditions
- Cystic Fibrosis Lung, Respiratory Infections, Recurrent, Chronic, Pseudomonas Aeruginosa
- Trial name
- NCT06016088
- Testing
- RSP-1502, Tobramycin inhalation solution
- Where
- 22 sites in United States, Australia
- Volunteers
- 71 people
- Sponsor
- Respirion Pharmaceuticals Pty Ltd
Hepatocellular Carcinoma
Utility of Abbreviated Magnetic Resonance Imaging as a Screening Tool for Hepatocellular Carcinoma in Cirrhotic Patients
The goal of this study is Utility of abbrevational magnetic resonance imaging as a screening tool for hepatocellular carcinoma in cirrhotic patients.
- Trial name
- NCT05716620
- Testing
- MRI
- Where
- India
- Volunteers
- 380 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
Chronic Hepatitis B
Efficacy and Safety of Ypeginterferon Alfa-2b in HBeAg Positive Chronic Hepatitis B
This study is a multi-center, randomized, open-label and positive controlled Phase II Clinical trial to assess efficacy and safety of Ypeginterferon alfa-2b, once a week, in 3 dose-groups: 90mcg, 135mcg and 180mcg, respectively…
- Trial name
- NCT01143662
- Testing
- Ypeginterferon alfa-2b, Peginterferon alfa-2a
- Where
- 39 sites in China
- Volunteers
- 205 people
- Sponsor
- Xiamen Amoytop Biotech Co., Ltd.
Shigellosis
Safety and Efficacy of the Bacteriophage Preparation, ShigActive™, in a Human Experimental Model of Shigellosis
The study is a first-in-human Phase 1/2a randomized, double-blind, placebo-controlled trial to assess the clinical safety and efficacy of ShigActive in healthy adults with experimental Shigella challenge.
- Trial name
- NCT05182749
- Testing
- bacteriophage
- Where
- United States
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Intralytix, Inc.
Chronic Hepatitis B
A Phase II Clinical Study of BW-20507 in Combination With PEG-IFNα for the Treatment of Hepatitis B
This is a randomized, open-label, multicenter phase II study to evaluate the efficacy and safety of BW-20507 in combination with PEG-IFNα in CHB patients
- Trial name
- HBV (NCT07135349)
- Testing
- BW-20507 with/without NUC, BW-20507 with/without NUC, Peg-IFNa
- Where
- 18 sites in China
- Volunteers
- 209 people
- Sponsor
- Shanghai Argo Biopharmaceutical Co., Ltd.
Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor
Development of Strategies to Increase Enrollment in Clinical Trials for Children With Cancer
RATIONALE: Taking part in a clinical trial may help children with cancer receive more effective treatment. PURPOSE: Determine why patients who are eligible for protocols made available through the Pediatric Oncology Group do not…
- Conditions
- Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor, Leukemia
- Trial name
- NCT00002485
- Testing
- psychosocial assessment and care
- Where
- 31 sites in United States, Canada and 2 more
- Volunteers
- 359 people
- Sponsor
- Children's Oncology Group
Hepatitis B, Chronic
Antiviral Therapy in Hepatitis B Virus (HBV)-Related Advanced Liver Disease Patients
This is a randomized, open label, phase IV, multicenter study for efficacy and safety of lamivudine versus entecarvir therapy in HBV-related advanced liver disease patients with high viral load and normal or slightly elevated…
- Trial name
- NCT00823550
- Testing
- Entecavir, Lamivudine
- Where
- South Korea
- Volunteers
- 462 people
- Sponsor
- Yonsei University
Hepatitis C
Identification of Viral Variants Involved in the Transmission of Hepatitis C and Characterization of Antigenic and Functional Properties of Their Envelope Glycoproteins
The study consists to Identify viral variants involved in the transmission of hepatitis C and characterize the antigenic and functional properties of their envelope glycoproteins at very early stage of infection (before…
- Trial name
- VINTAGE VHC (NCT02574884)
- Testing
- Blood sample (act specific of blood withdrawal for the study)
- Where
- France
- Volunteers
- 8 people
- Sponsor
- University Hospital, Tours
Hepatitis B, Liver Fibrosis
A Study in Reversing Hepatic Fibrosis or Cirrhosis Related to Hepatitis B Virus and Finding Biomarkers
The aim of our study is to validate the non-invasive model which was constructed by our previous study for evaluating liver fibrosis or cirrhosis caused by hepatitis B virus in mainland China and to find a therapeutic regimen to…
- Trial name
- NCT03568578
- Testing
- Entecavir 0.5 mg, Anluohuaxian Pill 12g
- Where
- 18 sites in China
- Volunteers
- 450 people
- Sponsor
- Peking University First Hospital
HCV Infection
Pharmacokinetics of Voxilaprevir in Adults With Normal Renal Function and Severe Renal Impairment
The primary objective of this study is to evaluate the pharmacokinetics, safety, and tolerability of voxilaprevir (formerly GS-9857) in participants with severe renal impairment and matched healthy control participants.
- Trial name
- NCT02402452
- Testing
- Voxilaprevir
- Where
- 4 sites in United States, Germany and 1 more
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Gilead Sciences
Chronic Hepatitis B
Activity of NCO-48 Fumarate in Treatment-Naive Adults With Chronic Hepatitis B
This is an open-label study evaluating multiple doses of NCO-48 Fumarate versus tenofovir alafenamide (TAF).
- Trial name
- NCT04629976
- Testing
- NCO-48 Fumarate 4 mg, NCO-48 Fumarate 20 mg, Tenofovir Alafenamide 25 mg
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Nucorion Pharmaceuticals, Inc.
Hepatitis C, Chronic
An Observational Study Examining the Use of Triple Combination Therapy With Boceprevir, Peginterferon Alfa-2a and Ribavirin in the Re-Treatment of Chronic Hepatitis C Patients
This prospective, national, multicenter, non-interventional study examined the use of triple combination therapy with boceprevir, pegylated interferon (peginterferon) alfa-2a and ribavirin in re-treating participants with…
- Trial name
- NCT02118597
- Testing
- Boceprevir, Simeprevir, Pegylated Interferon (Peginterferon) Alfa-2a
- Where
- 7 sites in Hungary
- Volunteers
- 19 people
- Sponsor
- Hoffmann-La Roche
Hepatitis C Virus
Safety Study of Recombinant Interferon Variant(PEG-IFN-SA) to Treat HCV Disease
The purpose of this study is to determine whether PEG-IFN-SA is safe, tolerant and effective in the treatment of HCV patients.
- Trial name
- PEG-IFN-SA (NCT01605513)
- Testing
- interferon
- Where
- China
- Volunteers
- 80 people
- Sponsor
- The First Hospital of Jilin University
Hepatitis B, Chronic
Early Response to Interferon Combined Short-Term Nucleoside Analogue Therapy in HBeAg(+) Chronic Hepatitis B
For HBeAg(+) patients, interferon is used for 12 weeks. On 12th week of treatment, If HBV DNA is undetectable (<1000 copies/ml), interferon is continued alone for one year.
- Trial name
- NCT00860626
- Testing
- interferon α plus nucleoside analogue, interferon α
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Sun Yat-sen University
Hepatitis C
A Study of TMC435 in Combination With Pegylated Interferon Alp\Fa-2a and Ribavirin in Patients Infected With Genotype 1 Hepatitis C Virus Who Never Received Treatment
The purpose of this study is to evaluate the efficacy of 4 different regimens of TMC435 in combination with peginterferon alfa-2a (PegIFNα-2a) and ribavirin (RBV), defined as the proportion of patients with sustained virologic…
- Trial name
- PILLAR (NCT00882908)
- Testing
- TMC435, Ribavirin (R), PegIFNα-2a (P)
- Where
- 71 sites in United States, Australia and 11 more
- Volunteers
- 386 people
- Sponsor
- Tibotec Pharmaceuticals, Ireland
Shigellosis
A Study to Determine If a New Shigella Vaccine is Safe, Induces Immunity and The Best Dose Among Kenyan Infants
In this study, the tetravalent bioconjugate candidate vaccine Shigella4V will be tested to obtain first-in-human data on its safety and immunogenicity in infants and to identify the preferred dose of Shigella4V in 9 month old…
- Trial name
- NCT04056117
- Testing
- Shigella 4V, MenACWY, Rabies
- Where
- 2 sites in Kenya
- Volunteers
- 597 people, healthy volunteers welcome
- Sponsor
- LimmaTech Biologics AG
Hepatitis B, Chronic
Combination Treatment With REP 2139-Ca and Pegasys in Patients With Chronic Hepatitis B
The REP 201 protocol is a small exploratory study assessing the antiviral effects and tolerability of REP 2139-Ca when used with a full course of pegylated interferon (48 weeks) in treatment naive patients or in patients already…
- Trial name
- NCT02726789
- Testing
- REP 2139-Ca, pegylated interferon, entecavir
- Volunteers
- 5 people
- Sponsor
- Replicor Inc.
Hepatitis C
Treatment of Hepatitis c by Using Direct-acting Antiviral
Patients with hepatitis c showed increased level of oxidative stress. Increased level of serum lipid peroxidation leads to the production of toxic mediators as malondialdehyde (MDA) which lead to disease progression.
- Trial name
- NCT05372874
- Testing
- Direct Acting Antivirals
- Volunteers
- 50 people
- Sponsor
- Tanta University
Hepatitis C
Study to Assess Clinical Outcomes in Chronic Hepatitis C Patients Previously Treated With Daclatasvir-Based Regimens
The purpose of this study is to assess long-term outcomes in subjects previously treated with daclatasvir-based therapy for chronic Hepatitis-C (CHC)
- Trial name
- NCT03366610
- Testing
- Non-interventional
- Where
- China
- Volunteers
- 199 people
- Sponsor
- Bristol-Myers Squibb